Novartis Korea's Sebivo to be of no NHI reimbursement.

Published: 2007-05-15 06:58:00

Updated: 2007-05-15 06:58:00

Novartis Korea expressed a deep regret about which the NHI reimbursement for Sebivo (telvibudin), a new therapy of chronic B hepatitis infection, was not granted by the final determination of the Health Insurance Review Agency, Drug Expert Review Commission and thereby chances for many patients w...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK